Neuronetics, Inc.NASDAQ: STIM

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Neuronetics, Inc. via GlobeNewswire

Summary by 6ix AI

Neuronetics, Inc., which makes the NeuroStar transcranial magnetic stimulation (TMS) depression treatment system and runs the Greenbrook psychiatry clinic network, said on November 18, 2026 that it had granted an inducement award of 9,000 restricted stock units to one non-executive employee, Julia Roussel.

Key details

  • Restricted stock units (RSUs) are promises to deliver company shares once set vesting dates are reached.
  • The award vests in three equal parts: one third on each of the first, second and third anniversaries of the grant date.
  • In accordance with Nasdaq Listing Rule 5635(c)(4), Neuronetics' Compensation Committee approved the award, which was made as a material inducement to the employee's employment with the company.
  • The award is subject to the terms of the company's 2020 Inducement Incentive Plan.

What’s still pending

  • Vesting of each part depends on the recipient's continued employment with the company through the applicable vesting date.

6ix AI wrote this summary from the release below and checked it against the release.

MALVERN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement award(s) to one non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), this award was approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Restricted stock units (“RSUs”)

NameNumber of Inducement
Plan RSUs
Vesting Schedule
Julia Roussel9,0001/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.

About Neuronetics
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Neuronetics Contact:
Investors:
Mark Klausner or Aman Patel
ICR Healthcare
443-213-0499
ir@neuronetics.com

Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

View original source (GlobeNewswire)Neuronetics, Inc. on 6ix

Earlier from Neuronetics

All Neuronetics news releases